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Cleveland, Ohio; and Chiba, JapanObjectives This study sought to assess stent-vessel interactions after drug-eluting stent (DES)
implantation in unprotected left main coronary artery (ULM) by frequency-domain optical coherence
tomography (FD-OCT).
Background Percutaneous coronary intervention using DES in ULM has been increasingly performed
in routine practice. Recently, FD-OCT assessments of DES-vessel interactions have been used as
surrogates for DES safety; however, there are no FD-OCT studies in ULM.
Methods We prospectively enrolled 33 consecutive patients with ULM disease treated with sirolimus-
(n ¼ 11) and everolimus-eluting stents (n ¼ 22). FD-OCT assessments were performed post-
percutaneous coronary intervention and at 9-month follow-up. Three different segments of ULM were
compared: distal (DIS), bifurcation (BIF), and ostial-body (BODY). The primary endpoints were
percentages of uncovered and malapposed struts at 9-month follow-up, and the secondary endpoint
was neointimal hyperplasia area.
Results We analyzed 25,873 stent struts. Signiﬁcant differences were demonstrated for percentage of
uncovered struts (3.4%, 11.7%, and 18.7%, respectively for DIS, BIF, and BODY; p < 0.05 for all the
comparisons). Malapposition was also more common in BODY (5.3%) than in DIS (0.6%) and BIF (2.0%)
segments (p < 0.05 for BODY vs. DIS, and BODY vs. BIF). Equivalent neointimal hyperplasia areas were
demonstrated in all segments. Acute malapposition rates led to different patterns of DES-vessel
interactions at 9-month follow-up.
Conclusions Distinct patterns of DES-vessel interactions were demonstrated in different segments of
ULM. Acute stent strut malapposition affects these ﬁndings. (J Am Coll Cardiol Intv 2013;6:1035–45)
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1036Indications of percutaneous coronary intervention (PCI)
using drug-eluting stents (DES) for unprotected left main
coronary artery (ULM) disease are increasing worldwide
(1–3). However, safety concerns regarding DES are ampli-
ﬁed in ULM due to the large amount of myocardium at
risk (4). Intravascular optical coherence tomography
(OCT) has been extensively validated against histology (5)
and is currently used as a surrogate for in vivo healing
assessment after DES implantation in clinical trials (6).
OCT studies have provided invaluable insights into vas-
cular reactions to stents (5,7,8), making this technology
an attractive tool to investigate DES interactions in the
setting of ULM PCI. Compared with a prior-generation
time-domain OCT system, the latest frequency-domain
optical coherence tomography (FD-OCT) has an increasedAbbreviations
and Acronyms
BIF = bifurcation
BODY = ostial-body
DES = drug-eluting stent(s)
DIS = distal
EES = everolimus-eluting
stent(s)
FD-OCT = frequency-domain
optical coherence
tomography
NIH = neointimal hyperplasia
SES = sirolimus-eluting
stent(s)
SIT = strut-level intimal
thickness
ST = stent thrombosis
TIMI = Thrombolysis In
Myocardial Infarction
ULM = unprotected left
main coronary arterypullback speed (up to 25 mm/s),
obviating the need for proximal
balloon occlusion during image
acquisition, and provides a larger
ﬁeld of view (w10 mm), enabling
evaluation of large vessels. We,
therefore, performed a compre-
hensive evaluation of acute and
late DES-vessel interactions of
lesions involving ULM distal
bifurcation using serial FD-OCT
imaging.Methods
Study population. A total of 54
consecutive patients underwent
PCI with DES in ULM from
March 2010 to September 2010,
and 33 fulﬁlled the inclusion
criteria to be enrolled in this
prospective single center (New
Tokyo Hospital, Chiba, Japan)study. Patients treated by single-stent strategy with crossover
from ULM to left anterior descending coronary artery
(LAD) were eligible if they had de novo obstructive
atherosclerotic disease in ULM related to myocardial
ischemia or stenosis >50% by angiographic assessment.
Exclusion criteria included congestive heart failure with left
ventricle ejection fraction <30%, ST-segment elevation
myocardial infarction, chronic kidney disease (serum creat-
inine >1.5 mg/dl) not on hemodialysis, inability to comply
with follow-up requirements, known allergy to antiplatelet
agents or contrast dye, and life expectancy <1 year. Patients
treated with 2-stent strategy (culotte, crush, mini crush)
were also excluded. FD-OCT was performed in all patients
post-PCI and at 9-month follow-up. The study protocol
was approved by the institutional review board and informedconsent was obtained for every patient before any interven-
tion was performed.
PCI procedure. All patients were treated with aspirin
(200-mg loading dose) and clopidogrel (300-mg loading
dose) at least 24 h before PCI. After stent implantation,
aspirin was maintained indeﬁnitely (200 mg/day), whereas
clopidogrel (75 mg/day) was continued for at least 1 year.
Cilostazol was also prescribed at least 3 months after PCI
(9). All patients received an intra-arterial bolus injection of
6,000 to 10,000 IU of heparin and intracoronary isosorbide
dinitrate (2 to 3 mg) before initial angiography. PCI was
performed by femoral or radial approaches using 6- or 7-F
guiding catheters. Sirolimus-eluting stents (SES) (Cypher,
Cordis, Miami Lakes, Florida) or everolimus-eluting stents
(EES) (Xience V, Abbott Vascular, Santa Clara, California;
and Promus, Boston Scientiﬁc, Natick, Massachusetts) were
implanted per the operator’s discretion with crossover single-
stent strategy. PCI success was deﬁned when <20% residual
stenosis with normal distal blood ﬂow (TIMI [Thrombolysis
In Myocardial Infarction] ﬂow grade 3) was achieved.
Procedural success was deﬁned as PCI success without any
in-hospital adverse events.
Quantitative coronary angiography analysis. Quantitative
coronary angiography was performed before PCI, after PCI,
and at 9-month follow-up. Angiographic measurements
were made in 2 matched orthogonal projections. Ofﬂine
analyses of digital coronary angiograms (CASSII, Pie-
Medical, Maastricht, the Netherlands) were performed by
an independent core laboratory (Cardiovascular Imaging
Core Laboratory, University Hospitals Case Medical
Center, Cleveland, Ohio) using validated quantitative
methods (10).
FD-OCT image acquisition and analysis. A conventional
angioplasty guidewire (0.014-inch) was advanced distal to
the region of interest, then the 2.7-F FD-OCT catheter
(Dragonﬂy, St. Jude Medical, St. Paul, Minnesota) was
advanced over the guidewire at least 10 mm beyond the
region of interest. The images were calibrated by automated
adjustment of the Z-offset and automated pullback was set
at 20 mm/s. Data were acquired using a commercially
available FD-OCT system (C7-XR, OCT Imaging System,
St. Jude Medical) after intracoronary administration of 50 to
200 mm of nitroglycerin through conventional guiding
catheters and were digitally stored. During imaging acqui-
sition, blood was displaced by injection of isosmolar contrast
dye (100%) with a power injector. FD-OCT pullbacks were
performed from LAD to the ostial-body part of ULM.
Image acquisition was performed in a similar fashion after
PCI and at 9-month follow-up. An independent core
laboratory (Cardiovascular Imaging Core Laboratory)
reviewed all FD-OCT images. The images were analyzed by
2 independent investigators blinded to the angiographic and
clinical data. FD-OCT analyses were performed using
dedicated software with an automated contour-detection
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1037algorithm (Off-line Review Software, version C.0.2, St. Jude
Medical). Commercially available dedicated software (Amira
5.4.2, Visage Imaging, San Diego, California) was used for
3-dimensional reconstruction of FD-OCT 2-dimensional
images. Only single-stent crossovers from ULM ostial-body
to LAD were analyzed. Aiming at obtaining a comprehen-
sive analysis, ULM was divided into 3 major segments, as
follows: ostial-body (BODY); bifurcation (BIF); and distal
(DIS) (Fig. 1). All cross-sectional images were initially
screened for quality assessment and excluded from analysis
if any portion of the stent was out of the screen, if a side
branch (except ULM bifurcation) occupied >45 of the
cross section, or if the image had poor quality caused by
residual blood, artifact, or reverberation (11). Qualitative
image assessment was performed in every frame, whereas
quantitative measurements were performed every 2 frames
(i.e., every 0.4 mm) (12) along the entire stented segment. In
BIF segments, cross sections were analyzed as previously
described (13). Strut-level intimal thickness (SIT) was
determined based on automated measurements performed
from the center of the luminal surface of each strut blooming
and its distance to the lumen contour (11). Struts covered by
tissue had positive SIT values, whereas uncovered orFigure 1. Representative FD-OCT Image and Schema
Unprotected left main was divided into 3 segments for the purpose of frequency-dom
(BODY); 2) bifurcation (BIF); 3) distal (DIS). Brown line represents OCT catheter. LCXmalapposed struts had negative SIT. Strut malapposition
was deﬁned as being when the negative value of SIT was
higher than the sum of strut thickness plus abluminal
polymer thickness, according to stent manufacturer speciﬁ-
cations, plus a compensation factor of 20 mm to correct for
strut blooming (8,12). Tissue protrusion was deﬁned as
a tissue prolapse between stent struts that directly correlates
with the underlying plaque, without abrupt transition and
different optical properties (13). Presence of thrombus and
dissections were determined as previously described (14,15).
Stent imaging completeness was deﬁned when stent struts
were observed in at least 3 quadrants at each major segment.
FD-OCT derived malapposition values were obtained by
means of 360 chords, distributed between the lumen and
stent contours. DES–vessel interactions comprise acute
modiﬁcations induced by DES implantation in either vessel
or stent (i.e., tissue protrusion, acute malapposition), as well
as 9-month follow-up FD-OCT surrogates for vessel heal-
ing response (i.e., stent strut coverage, neointimal hyper-
plasia [NIH], malapposition).
In order to assess the impact of stent strut malapposition
after PCI (acute stent strut malapposition) in DES-vessel
interactions at 9-month follow-up, FD-OCT pullbacksain optical coherence tomography (FD-OCT) analyses, as follows: 1) ostial-body
¼ left circumﬂex.
Table 1. Baseline Clinical Characteristics (N ¼ 33)
Age, yrs 67.7  7.5
Men 27 (81.8)
BMI, kg/m2 23.9  3.6
Hypertension 27 (81.8)
Diabetes 18 (54.5)
HbA1c, % 6.5  1.6
Dyslipidemia 26 (78.8)
Current smoker 9 (27.3)
Obesity 15 (45.5)
Prior MI 2 (6.1)
Prior CABG 0 (0)
Post PCI 9 (27.3)
Peripheral arterial disease 6 (18.2)
Hemodialysis 4 (12.1)
LV ejection fraction, % 58.2  8.6
Baseline creatinine non-HD, mg/dl 0.82  0.27
Baseline eGFR non-HD 64.0  29.9
Congestive heart failure <30, % 0 (0)
Stable angina 25 (75.8)
Unstable angina 7 (21.2)
NSTEMI 1 (3.0)
Values are mean  SD or n (%).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; eGFR ¼ estimated glomerular
ﬁltration rate; HbA1c ¼ glycosylated hemoglobin; HD ¼ hemodialysis; LV ¼ left ventricular;
MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction;
PCI ¼ percutaneous coronary intervention.
Table 2. Angiographic and Procedure Characteristics (N ¼ 33)
Medina classiﬁcation
(1.1.1) 7 (21.2)
(1.1.0) 11 (33.3)
(1.0.1) 0 (0)
(1.0.0) 6 (18.2)
(0.1.1) 2 (6.1)
(0.1.0) 7 (21.2)
(0.0.1) 0 (0)
Quantitative coronary angiography
Pre-procedure
MLD, mm 1.1  0.4
RVD-mean, mm 3.6  0.5
RVD-proximal, mm 4.6  0.8
RVD-distal, mm 3.0  0.5
% DS 69.2  11.2
Post-procedure
MLD, mm 3.3  0.5
RVD-mean, mm 3.6  0.4
RVD-proximal, mm 4.7  0.6
RVD-distal, mm 3.1  0.5
% DS 11.9  6.1
9-month follow-up
MLD, mm 2.8  0.4
RVD-mean, mm 3.6  0.4
RVD-proximal, mm 4.6  0.6
RVD-distal, mm 3.0  0.4
% DS 19.3  10.9
Procedure characteristics
Stent type
Number of patient with SES 11 (33.3)
Number of patient with EES 22 (66.7)
Number of stents in a patient 1.3
Average stent diameter, mm 3.5  0.1
Average stent length, mm 21.8  5.5
Pre-dilation 23 (69.7)
Post-dilation to ULM body 30 (90.9)
KBT 29 (87.9)
Post-balloon diameter, mm 4.5  1.5
Max inﬂation pressure, atm 18.7  7.3
Values are n (%) or mean  SD
% DS ¼ percentage of diameter stenosis; EES ¼ everolimus-eluting stent(s); KBT ¼ kissing
balloon technic; MLD ¼ minimal lumen diameter; RVD ¼ reference vessel diameter; SES ¼
sirolimus-eluting stent(s); ULM ¼ upper left main.
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1038were aligned based on ﬁduciary points (distal stent edge,
branches, and calciﬁcations) and the major segments (i.e.,
BODY, BIF, and DIS) along the stented segment were
automatically subsegmented in 2.5-mm intervals (subseg-
ments) (7). The median percentage of stent strut malap-
position following PCI for each of the major segments was
used for reference. Subsegments with rates of malapposition
that were lower than the reference value for that speciﬁc
major segment were labeled as the “low” (percentage of acute
malapposition) group, whereas subsegments with percent-
ages of malapposition higher than the median value were
labeled as the “high” (percentage of acute malapposition)
group.
Endpoints. The primary endpoints were the percentage of
uncovered and malapposed stent struts assessed by FD-
OCT at 9-month follow-up in different segments (BODY/
BIF/DIS). The secondary endpoint was NIH area at 9-
month follow-up in each segment. The impact of the
percentage of malapposed stent struts after PCI in vascular
response at 9-month follow-up was also evaluated. Major
adverse cardiac events (cardiac death, coronary artery bypass
graft, acute myocardial infarction, stent thrombosis based on
Academic Research Consortium deﬁnitions of deﬁnite/
probable (16), target vessel revascularization, and target
lesion revascularization) were assessed by ofﬁce visits or by
phone calls at 9-month follow-up.Statistical methods. All statistical analyses were performed
using SAS software (version 9.2, SAS Institute, Cary, North
Carolina), and statistical signiﬁcance was assessed at the 0.05
level. Continuous variables are expressed as mean  SD, and
categorical variables are expressed as counts and percentages.
For major segments and 2.5-mm subsegment analyses,
differences between time points, distinct baseline rates of
malapposition (i.e., low and high group), as well as differ-
ences observed between each group (DIS vs. BIF vs.
BODY) were evaluated using generalized estimating equa-
tions with exchangeable correlation to account for the
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1039clustering of values within each subject after adjusting for
stent types. To estimate differences at frame level, multilevel
mixed model, which can address random effects at segment
and subject levels, was used for binary and continuous
outcomes comparisons. Mixed effects model was used to
estimate correlation coefﬁcient between malapposed struts
percentage and mean lumen area after PCI with repeated
observations.
Results
Patient characteristics and image acquisition. All 33 patients
underwent angiography and FD-OCT after PCI and at
9-month (mean 286  49.8 days) follow-up. Baseline
clinical characteristics are reported in Table 1, and angio-
graphic and procedural characteristics are shown in Table 2.
No complications were identiﬁed. Most patients underwent
kissing-balloon technique, followed by in-stent post-dilation
in the BODY segment. Eleven patients were treated with
SES, and 22 patients were treated with EES. We planned
a single-stent strategy to treat all the cases; nevertheless, in 5
patients, we had to use an additional stent in the proximalTable 3. FD-OCT Findings at Serial Time Points After DES Implantation
N ¼ 33 (SES: n ¼ 11, EES: n ¼ 22)
Post-P
DIS BIF
Segments 32 33
Total length, mm 274 77.4
Analyzed struts 6,743 2,087
Total frames 712 214
Not analyzable frames 4.9 (35/712)* 0.9 (2/2
Lumen area, mm2 8.82  1.80*yz 11.28  2.
Stent area, mm2 8.41  1.67*y 10.81  2.
Embedded struts 5.9 (395/6,743) 5.6 (100/1
Protruding area, mm2 0.22  0.20*y 0.32  0.
Malapposed struts 2.9 (198/6,743)*yz 11.2 (200/1
Uncovered NA NA
Neointimal thickness, mm NA NA
Mean neointimal area, mm2 NA NA
Mean malapposition area, mm2 0.12  0.23* 0.27  0.
Lumen volume, mm3 75.25  43.84yz 28.67  9.
Stent volume, mm3 71.79  42.02y 27.50  8.
Neointimal volume, mm3 NA NA
Protruding volume, mm3 1.84  1.55y 0.82  0.
Mean malapposition volume, mm3 0.94  0.93* 0.66  0.
Maximum malapposition distance, mm 0.28  0.14* 0.32  0.
Maximum length of segments with uncovered struts, % NA NA
Maximum length of segments with malapposed struts, % 21.25  21.92*yz 47.20  38
Thrombus 15.6 (5/32)z 6.1 (2/3
Values are n, % (n/N), or mean  SD. *p < 0.05, between DIS and BODY segments. yp < 0.05 between D
and BODY segments.
BIF ¼ bifurcation; BOSY ¼ ostial-body; DES ¼ drug-eluting stent(s); DIS ¼ distal; EES ¼ everolimus-e
SES ¼ sirolimus-eluting stents.LAD, distal to the ULM stent, due to distal stent edge
dissections, whereas in 5 patients, a second stent was
required due to the long length of the diseased segment.
One patient after PCI and 2 patients at 9-month follow-up
had inadequate DIS segment stent evaluation due to
incomplete FD-OCT pullback imaging. These segments
(not the patients) were excluded from analysis.
FD-OCT ﬁndings. A total of 25,873 stent struts were
analyzed. After PCI, progressively larger stent and lumen
areas were identiﬁed in DIS, BIF, and BODY segments,
respectively (Table 3). At 9-month follow-up, although stent
areas remained unchanged compared to those following PCI,
lumen areas were signiﬁcantly reduced, preserving the
differences between the segments (Table 3). Percentage of
uncovered stent struts at 9 months was signiﬁcantly different
between each segment (DIS 3.4%, BIF 11.7%, and BODY
18.7%; p < 0.05 for all the comparisons).
Acute malapposition was signiﬁcantly more common in
BODY and BIF compared with the DIS segment (Table 3,
Fig. 2). Signiﬁcant reduction in percentage of malapposed
stent struts was observed at 9-month follow-up in all
segments (Table 3, Fig. 3); however, while comparable lowCI 9-Month Follow-Up
BODY DIS BIF BODY
33 31 33 33
213 265.4 71.6 212.6
4,915 5,934 1,705 4,489
557 686 198 549
14) 0.5 (3/557)* 8.9 (61/686)*y 0.0 (0/198)y 0.2 (1/549)*
37yzx 14.30  3.12*zx 7.63  2.27*yz 9.99  2.91yzx 13.28  3.14*zx
10yx 13.56  2.76*x 8.53  1.91*y 10.82  2.27yx 13.79  2.76*x
,788)x 4.4 (214/4,915)x NA NA NA
35y 0.39  0.39* NA NA NA
,788)yz 13.9 (683/4,915)*z 0.6 (38/5,934)*z 2.0 (31/1,542)zx 5.3 (237/4,489)*zx
NA 3.4 (202/5,934)*y 11.7 (200/1,705)yx 18.7 (840/4,489)*x
NA 0.12  0.13y 0.14  0.16yx 0.09  0.12x
NA 1.06  0.86 1.09  0.98 0.99  0.89
42zx 0.42  0.98*x 0.08  0.31* 0.14  0.31zx 0.26  0.75*x
17yzx 98.89  55.06zx 64.51  39.50*yz 23.84  12.62yzx 88.11  43.45*zx
72yx 93.96  54.04x 72.01  42.54y 25.83  11.98yx 91.49  44.58x
NA 8.88  6.99y 2.57  2.13yx 6.55  5.53x
54yx 2.71  2.72x NA NA NA
76zx 2.85  3.84*zx 0.67  1.56* 0.31  0.54x 1.66  2.46*zx
16x 0.46  0.30*x 0.36  0.26 0.40  0.20 0.58  0.46
NA 32.67  26.45*y 55.41  35.06y 65.51  29.19*
.98yz 56.41  39.92*z 4.56  9.67*z 10.42  24.55zx 22.31  30.19*zx
3) 9.1 (3/33) 0 (0/31)z 0 (0/33) 0 (0/33)
IS and BIF segments. zp < 0.05 between post-PCI and follow-up segments. xp < 0.05 between BIF
luting stents; FD-OCT ¼ frequency-domain optical coherence tomography; NA ¼ not applicable;
Figure 2. Relationship of Malapposed Struts Percentage and
Mean Lumen Area After PCI
Linear regression of malapposed struts percentage versus mean lumen area
(mm2) after percutaneous coronary intervention (PCI). Blue, red, and green
dots correspond, respectively, to DIS, BIF, and BODY. Abbreviations as in
Figure 1.
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1040rates of malapposition were demonstrated in BIF (0.6%) and
DIS (2%), signiﬁcantly higher rates were observed in BODY
(5.3%) (Table 3). The temporal evolution of stent strut
malapposition is represented in Figure 4. NIH thickness of
BIF segment was signiﬁcantly higher than it was for DIS
and BODY segments, whereas NIH areas were comparable
between the groups. There were no thrombus related to
uncovered or malapposed stent struts at 9-month follow-up
(Table 3).
When EES and SES were compared, similar rates of acute
malapposition were observed in BODY and DIS segments,
whereas signiﬁcantly higher rates of malapposition were
demonstrated in BIF segments treated with SES (Online
Table 1). At 9-month follow-up, a trend toward higher rates
of malapposition with SES compared with EES was also
observed in DIS and BIF segments. In addition, signiﬁcantlyFigure 3. Time Course of Malapposed Struts Percentage After Stent Implantatio
Percentage of malapposed struts after PCI and at 9-month follow-up in (A) DIS, (B)
percentages of uncovered and malapposed struts at each time point for BIF and uphigher rates of uncovered struts were observed in DIS
segments treated with SES versus EES, and the same trend
was observed in BIF and BODY segments. Conversely, there
was more NIH after EES compared with SES (Online
Table 2).
The impact of acute stent strut malapposition in stent-
vessel interactions at 9-month follow-up was evaluated. The
percentage of uncovered stent struts was signiﬁcantly
reduced in the low compared with the high group in DIS
and BODY segments, with the same trend in BIF segment
(Fig. 5). Somewhat expected, 9-month malapposition rates
and areas were higher in the high than in the low group in
BODY segment, while a similar trend was demonstrated
in BIF and DIS segments. There was no impact of acute
malapposition in the magnitude of NIH proliferation in
the DIS segment, whereas signiﬁcantly reduced NIH area
leading to less percentage stenosis was shown in BODY,
with a similar trend in the BIF segment (Table 3, Fig. 5).
Figure 6 shows the representative acute malapposed stent
struts after PCI, which persisted as uncovered malapposed
stent struts at 9-month follow-up (Figs. 6A to 6D). We also
made a reconstruction of 3-dimensional FD-OCT images of
pullback following PCI (Figs. 6E to 6H) and 9-month
follow-up (Figs. 6I to 6L).
Clinical outcomes. All patients were taking dual antiplatelet
therapy at 9-month follow-up. Target lesion revasculariza-
tion occurred in 2 patients due to in-stent restenosis and in 1
patient due to lesion progression in the LAD. There was no
additional adverse cardiac event (Table 4).Discussion
The present study provides novel FD-OCT insights into
acute and late outcomes of DES implantation in lesions
involving ULM bifurcation. The main observations were
as follows. 1) In spite of modern high pressure balloonn
BIF, and (C) BODY segments. Red dashed lines represent mean  SEM of the
per left main BODY segments.
Figure 4. Subsegmental Analysis of the Temporal Evolution of Stent Strut Malapposition
Bar graphs depict the number of subsegments with malapposition (A, C, E) and volumes of malapposition (B, D, F) after PCI and at 9-month follow-up. Open bars
represent acute and persistent malapposition after PCI and at 9-month follow-up, respectively. Solid bars represent late acquired malapposition. Note that persistent,
as well as late acquired malapposition assessments were based on the evaluation of coregistered subsegments after PCI and at 9-month follow-up. Abbreviations as in
Figure 1.
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1041inﬂation techniques, stent malapposition remains a common
phenomenon immediately after DES implantation in ULM,
likely due to disproportionate larger sizes of left main
BODY when compared to stent sizes available, leading to
stent undersizing. 2) Acute and late DES-vessel interactions
vary among different segments of ULM (DIS, BIF, and
BODY) and stent type. 3) Stent malapposition in ULM is
mostly associated with decreased neointimal proliferation,without apparent increase in thrombus formation. 4) SES is
associated with a higher percentage of malapposition and
uncovered struts than are EES in ULM.
Substantial advancements in techniques and devices,
as well as in adjunctive pharmacology, have led to an
increase in PCI as a treatment of obstructive atherosclerotic
disease in ULM (3). However, ULM remains a high-risk
anatomical setting, in which stent thrombosis (ST) and/or
Figure 5. Graph Representation of the Impact of Baseline Malapposition Rates in Vascular Response at 9-Month Follow-Up
Comparison of follow-up (F/U) frequency-domain optical coherence tomography assessments between 2 groups with different baseline malapposition rates (i.e., low
and high groups) in different major segments of unprotected left main (DIS, BIF, and BODY). Impact of malapposition at baseline in the following at 9-month follow-up
are demonstrated: (A) uncovered struts percentage, (B) malapposed struts percentage, (C) neointimal hyperplasia (NIH), (D) malapposition area, (E) NIH area, and (F)
percentage area stenosis. Error bars represent  SEM; p value calculated by generalized estimating equations model shows baseline malapposed struts percentage
status ﬁxed effects after adjustment of stent type. Abbreviations as in Figure 1.
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1042restenosis can be catastrophic (17–20). The rationale for
assessing DES-vessel interactions by means of a high-
resolution intravascular imaging modality in vivo as surro-
gate for DES safety was primarily based on post-mortem
studies, which suggested that delayed healing, inﬂammation,
and malapposition were associated with ST (21).Intravascular OCT enables strut-level assessment of
coverage and malapposition in vivo with high accuracy
(6,8,15,22,23). A recent OCT study showed that uncovered
and malapposed stent struts, as well as their heterogeneous
distribution along the stented segment, were more common
in patients with than in those without ST (24). Therefore,
Figure 6. Uncovered and Malapposed Stent Struts in ULM Detection by 2D and 3D FD-OCT Images After PCI and at 9-Month Follow-Up
Green, white, and red asterisks correspond, respectively, to upper left main (ULM) BODY, left circumﬂex artery, and left anterior descending artery.
(A) Two-dimensional (2D) FD-OCT longitudinal view of post-PCI ULM is shown. The region highlighted by the white dashed line corresponds to the cross section
represented in (C); malapposed stent struts (white arrows) are depicted. The longitudinal view of the same region at 9-month follow-up demonstrates persistence of
malapposed/uncovered stent struts (B), which can be better visualized in D (white arrows). (E) Three-dimensional (3D) reconstruction of the FD-OCT pullback is shown
in A, in which malapposed stent struts are identiﬁed (white arrow). (F) The ULM is divided in 2 parts, which are represented as ﬂattened images (G,H), showing
uncovered stent struts after PCI. (I) A 3D reconstruction of the 9-month follow-up pullback is shown (B) and reveals persistence of malapposed/uncovered struts
(white arrow). Note that when the image is divided in 2 parts (J), which are represented as ﬂattened images (K,L), a heterogeneous pattern of stent coverage is
demonstrated by higher rates of uncovered struts in BODY than in the left anterior descending artery (K). Abbreviations as in Figures 1 and 2.
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1043the assessment of DES-vessel interactions in different
segments of ULM could play an important role in better
understanding the mechanisms of stent failure in this
scenario. We recently demonstrated the safety and feasibility
of evaluating ULM with FD-OCT versus intravascular
ultrasound (25). In the present study, we showed that larger
segments of ULM had higher rates of uncovered stent struts
(i.e., DIS < BIF < BODY). Despite marked improvement
in malapposition rates at 9-month follow-up compared with
post-PCI in all segments of ULM (Fig. 3), larger vessel
segments remained with higher percentages and areas of
stent strut malapposition (Table 3, Fig. 4). Indeed,malapposition rates and volumes were larger than previously
observed in non-ULM settings (26).
The division of the stented segment in 2.5-mm subseg-
ments enabled us to demonstrate that in-stent regions with
high percentages versus those with low percentages of
malapposition after PCI had greater impacts on vascular
response at 9-month follow-up (Fig. 5). These effects were
more pronounced in the largest segment of ULM (i.e.,
BODY segment), in which neointimal proliferation might
not have been sufﬁcient to cover stent struts adequately
and to promote resolution of malapposition at 9-month
follow-up. Similar observations were recently reported for
Table 4. Clinical Outcomes: MACE
Cardiac death 0 (0.0)
CABG 0 (0.0)
AMI 0 (0.0)
ST 0 (0.0)
TVR 1 (3.0)
TLR 2 (6.1)
Values are n (%).
AMI ¼ acute myocardial infarction; CABG ¼ coronary artery bypass graft; MACE ¼ major
adverse cardiac events; ST ¼ stent thrombosis; TLR ¼ target lesion revascularization;
TVR ¼ target vessel revascularization.
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1044non-ULM lesions (27). To our knowledge, this is the ﬁrst
intravascular imaging observation of acute DES malap-
position and its impact in DES-vessel interactions at follow-
up in lesions involving ULM bifurcation. Although all the
procedures included in our study were conducted by expe-
rienced operators in a high-volume PCI center (1,800 PCI/
year, 180 left main PCI/year) and in-stent post-dilations
with noncompliant balloons at high pressures were per-
formed in 90.9% of the cases, acute malapposition rates
identiﬁed by FD-OCT seemed relatively high, mostly in
BIF and BODY segments. Therefore, we were able to
identify, by means of high-resolution intravascular imaging
(28), signiﬁcant room for improvement in the technique of
DES implantation in ULM (i.e., using larger stents and/or
larger balloons for post-dilation in larger segments). This
seems particularly important as there is increasing evidence
linking late stent malapposition (persistent and acquired) to
late and very late ST (29). Whether FD-OCT guidance can
improve ULM PCI acute results and long-term outcomes is
yet to be determined, as PCI procedures in our study were
not FD-OCT–guided; hence, additional interventions (i.e.,
post-dilation with higher pressure or larger balloons) based
on FD-OCT information were not performed.
In spite of the demonstration of higher rates of un-
covered and malapposed stent struts in larger segments of
ULM, no thrombus or clinically evident ST were identiﬁed
in our series at 9-month follow-up. However, our small
sample size does not allow meaningful conclusions regarding
such a rare adverse event. Finally, it is known that coronary
bifurcations are more prone to develop in-stent restenosis
than nonbifurcated lesions are (30), which is likely due to
regions of low shear stress and different ﬂow patterns (31).
We demonstrated, for the ﬁrst time, different degrees of
NIH proliferation in distinct segments of ULM with higher
NIH thickness in BIF compared with BODY and DIS
segments. It is important to stress, however, that NIH area
(which was comparable between different segments) rather
than NIH thickness was our secondary, previously speciﬁed
endpoint; therefore, although an interesting ﬁnding, the
difference demonstrated in the latter should be considered
explorative. Future validation of our ﬁndings is warranted.Study limitations. We were able to demonstrate, for the ﬁrst
time, vascular response after the implantation of DES in
ULM by means of high-resolution imaging; however, this
pilot study was designed to provide seminal insights on ULM
PCI withDES to be explored in future large trials. Hence, the
relatively small sample size precludes deﬁnitive conclusions
regarding clinical outcomes. Incomplete blood clearance at
the ULM ostium might impair adequate FD-OCT assess-
ments; nevertheless, we have demonstrated previously that
only a very short segment of ostial ULM is affected (25). This
paper includes only a population with lesions involving distal
ULM; therefore, while this is the most prevalent situation in
clinical practice, the results should not be extrapolated to
lesions located in ULM shaft and ostium.
Conclusions
The present study demonstrates the distinct patterns of
DES-vessel interactions in different segments, DIS, BIF,
and BODY of ULM. Furthermore acute stent strut mal-
apposition affects the DES-vessel interactions.
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